Printer Friendly

THE LIPOSOME COMPANY SELLS ADDITIONAL 450,000 SHARES AS PART OF STOCK OFFERING

 THE LIPOSOME COMPANY SELLS ADDITIONAL 450,000 SHARES
 AS PART OF STOCK OFFERING
 PRINCETON, N.J., March 18 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) announced today that the underwriter of the company's recent stock offering has exercised its option to purchase an additional 450,000 shares, at a price to the public of $13.75 per share, to cover over-allotment. The Liposome Company previously announced that it had successfully completed an offering of 3 million shares of common stock, at a price of $13.75 per share, raising gross proceeds of $41.25 million with net proceeds to the company of $38.6 million. Totals for the offering, including the overallotment option exercised today, now stand at 3,450,000 shares sold, with gross proceeds to The Liposome Company of $47,437,500, and net proceeds of $44,453,500. Hambrecht & Quist Incorporated was the sole underwriter of the offering.
 Proceeds from the offering are expected to be used for the development and clinical testing of the company's self-funded products, including TLC G-65 and TLC C-53. A portion of the proceeds may be used to expand the company's research activities and manufacturing facilities, to develop its marketing and distribution capabilities, and for other general corporate purposes.
 TLC G-65 is a proprietary, injectable liposomal aminoglycoside antibiotic, which is currently in Phase II clinical studies for the treatment of Mycobacterium avium-intracellulare (MAI) in AIDS patients. MAI is the most common systemic infection in people with AIDS, seen in up to 50 percent of AIDS patients. There are currently no drugs approved by the FDA for the treatment of disseminated MAI. Early Phase II results with TLC G-65 demonstrated that the drug was active and well tolerated. An additional safety and pharmacology study examining a more intensive dosing regimen has been completed and demonstrated good tolerability. A multicenter Phase II trial using the more intensive dosing regimen recently began in the United States. In addition, Phase III trials using a multi-drug regimen are expected to start in Europe in 1992. The Liposome Company owns all rights to TLC G-65 and plans to market the drug itself in the United States.
 TLC C-53 is a proprietary, injectable liposomal prostaglandin E1 (PGE1), which is being developed as a cell adhesion antagonist. It appears to function as a unique "universal off switch" that is believed to prevent platelets, neutrophils, and endothelial cells from being "turned on," and may also deactivate these cells after they have been "turned on," regardless of what stimulatory factors are present. When these cells are "turned off" or deactivated, they should not adhere to the cells to which they normally would, following stimulation. By so doing, it appears that TLC C-53 stops the cell adhesion that can lead to a variety of inflammatory and vaso-occlusive conditions including Adult Respiratory Distress Syndrome (ARDS), restenosis following angioplasty, reperfusion injury during heart attacks, sepsis/trauma syndrome, and others. Positive results have been seen in animal experiments in models of ARDS and Acute Myocardial Infarction (AMI) with TLC C-53. The Liposome Company plans to start clinical trials with TLC C-53 in 1992.
 Dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of life-threatening illnesses.
 -0- 3/18/92
 /CONTACT: Anne Van Lent, senior vice president and chief financial officer of Liposome Company, 609-452-7060/
 (LIPO) CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: OFR


SH-OS -- NY066 -- 9330 03/18/92 15:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:585
Previous Article:CP&L DIRECTORS DECLARE DIVIDENDS
Next Article:JACOR ANNOUNCES FINANCIAL RESULTS
Topics:


Related Articles
LIPOSOME COMPANY COMPLETES STOCK OFFERING OF 3 MILLION SHARES
LIPOSOME COMPANY, INC. COMPLETES $57 MILLION PREFERRED STOCK OFFERING
THE LIPOSOME COMPANY SELLS ADDITIONAL 360,000 DEPOSITARY SHARES AS PART OF STOCK OFFERING
THE LIPOSOME COMPANY, INC. FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING OF 3,000,000 SHARES OF COMMON STOCK
THE LIPOSOME COMPANY, INC. COMPLETES OFFERING OF 3,000,000 SHARES OF COMMON STOCK
THE LIPOSOME COMPANY, INC. SELLS ADDITIONAL 450,000 SHARES AS PART OF COMMON STOCK OFFERING
THE LIPOSOME COMPANY, INC. ANNOUNCES REDEMPTION OF 50% OF CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
THE LIPOSOME COMPANY SETS FEBRUARY 23, 1996 AS RECORD DATE RELATING TO THE REDEMPTION OF 50 PERCENT OF CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
THE LIPOSOME COMPANY, INC. COMPLETES CALL OF 50% OF CONVERTIBLE PREFERRED STOCK
Investor Purchases 1.0 Million Shares of The Liposome Company Common Stock

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters